Elan stays focused on drug technology spin-off

With its drug delivery revenue up sharply in the first quarter, Ireland's Elan says that investors appear bullish about a planned spin-off of the Elan Drug Technologies unit. Analysts say that the delivery arm could be worth close to a billion dollars. And executives say that this time around they expect to close a deal.

"When we looked at this in 2008, it was more financially driven. We didn't have the financial resources that we now have having done the transaction with Johnson & Johnson," Chief Financial Officer Shane Cooke told a news conference last week. "The focus this time is more on strategic benefits, therefore it is not something you have to do in a certain time frame because of a financial obligation."

Chief Executive Kelly Martin, though, insisted that the numbers have to be right before a sale goes through. "Obviously it doesn't help when we're talking to them (investors) that screens are red with huge, negative numbers."

- read the Reuters story
- here's the report from In-Pharma Technologist

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.